

<b>Division of Compensation Analysis and Support</b> <b>Program Evaluation Report</b>	Document Number: DCAS-PER-034 Effective Date: 12/9/2011 Revision No. 0
<b>Harshaw Chemical Company TBD Revision</b>	
Page 1 of 2	
Author: <u>Signature on file</u> Dave Allen, HP Team Leader	Date: <u>12/9/2011</u> Supersedes: None
Approval: <u>Signature on file</u> J.W. Neton, Associate Director for Science	Date: <u>12/9/2011</u>

RECORD OF ISSUE/REVISIONS			
ISSUE AUTHORIZATION DATE	EFFECTIVE DATE	REV. NO.	DESCRIPTION
12/9/2011	12/9/2011	0	New document to determine affect of revising the Harshaw TBD on previously completed claims.

**1.0 Description**

Revision 1 of the Harshaw Chemical Company Technical Basis Document (ORAUT-TKBS-0022) was issued on 6/2/2009. This document superseded the previous revision issued 8/17/2007.

**2.0 Issue Evaluation**

Several editorial changes and clarifications were included in the revision however these changes do not affect the estimated dose. Some changes may have decreased the dose but the only significant increase in the dose estimate is caused by an increase in the estimated intake rate for type S uranium from 12/1/1949 to 12/31/1953. The values are listed in Table 5-6 of both revisions.

**3.0 Plan for Resolution or Corrective Action**

**3.1 Determining the potential population of claims**

The criteria used to determine the population of claims potentially affected by this revision are:

1. Probability of Causation (PC) less than 50%;
2. Most recent version of the dose reconstruction approved by DCAS on or prior to June 2, 2009
3. Employed at the Harshaw Chemical Company between December 1, 1949 and December 31, 1953.

These criteria were used to generate the list of 6 potentially affected claims.

<b>Division of Compensation Analysis and Support Program Evaluation Plan</b>	Document Number: DCAS-PER-034
Effective Date: 12/9/2011      Revision No. 0	Page 2 of 2

**3.2 Determination of claims which will not change due to TBD revision.**

Of the six claims meeting the selection criteria, one was not affected because the intake was originally calculated using the individuals own bioassay data. The current revision of the TBD indicates this data should still be used if available so no change would occur to the dose estimate based on the TBD revision.

The dose for each of the remaining 5 claims was recalculated using all current dose reconstruction methods including the current version of the TBD. From that recalculated dose, a new probability of causation was determined. The new probability of causation was less than 45% for each of the five claims. Therefore none of the claims would now exceed a PC of 50% and so NIOSH will not ask DOL to return any of the previously completed Harshaw Chemical Company claims based on the revision to the TBD.